

Synthesis of 6-aryl-6,6a,7,9a-tetrahydro-5*H*-cyclopenta[*c*]-1,7- and -1,8-phenanthrolines

A. G. Tolstikov, R. G. Savchenko, E. S. Lukina, R. M. Limantseva, and V. N. Odinkov*

*Institute of Petrochemistry and Catalysis, Russian Academy of Sciences,
141 prosp. Oktyabrya, 450075 Ufa, Russian Federation.
Fax: +7 (347) 284 2750. E-mail: odinkov@anrb.ru*

A three-component acid-catalyzed cyclocondensation of 5-aminoquinoline and 5-aminoisoquinoline with aromatic aldehydes and cyclopentadiene leads to (6*S**,6*aR**,9*aS**)-6-aryl-6,6*a*,7,9*a*-tetrahydro-5*H*-cyclopenta[*c*]-1,7- and (6*S**,6*aR**,9*aS**)-6-aryl-6,6*a*,7,9*a*-tetrahydro-5*H*-cyclopenta[*c*]-1,8-phenanthrolines.

Key words: three-component condensation, Povarov reaction, 5-aminoquinoline, 5-aminoisoquinoline, aromatic aldehydes, cyclopentadiene, tetrahydro-1,7-phenanthrolines, tetrahydro-1,8-phenanthrolines.

Phenanthroline tetrahydro derivatives, being analogues of alkaloids and diazasteroids, possess a high potential of biological activity.^{1,2} Commonly, they are synthesized by the reaction of aminoquinolines with carbonyl compounds.³ There is another very promising approach to the synthesis of diazasteroids, which is based on a three-component condensation of aminoquinolines with formaldehyde and cyclopentadiene.^{4,5}


We were the first to study an acid-catalyzed one-step cyclocondensation of aminoquinolines with aromatic aldehydes and cyclopentadiene.

The reaction of 5-aminoquinoline (**1**) and 5-aminoisoquinoline (**2**) with aromatic aldehydes (benzaldehyde (**3**),

m-chloro- (**4**), *o*-fluoro- (**5**), and *p*-trifluoromethylbenzaldehydes (**6**)) and cyclopentadiene gave earlier unknown tetrahydro-1,7- and tetrahydro-1,8-phenanthrolines annulated to cyclopentene, which belong to the class of 4,11-diazasteroids.⁵

The reaction went smoothly when 2,2,2-trifluoroethanol was used as a solvent (room temperature, 2–3 h, catalyst trifluoroacetic acid (TFA)) and led to the target 6-aryl-6,6*a*,7,9*a*-tetrahydro-5*H*-cyclopenta[*c*]-1,7- (**7–10**) and 6-aryl-6,6*a*,7,9*a*-tetrahydro-5*H*-cyclopenta[*c*]-1,8-phenanthrolines (**11–14**) (Scheme 1). Running the reaction in acetonitrile^{6–8} commonly used for such processes led only to the corresponding Schiff bases. It should be

Scheme 1



Ar = Ph (**3**, **7**, **11**), *m*-Cl-C₆H₄ (**4**, **8**, **12**), *o*-F-C₆H₄ (**5**, **9**, **13**), *p*-CF₃-C₆H₄ (**6**, **10**, **14**)

noted that in the cases when an amino group was located on the pyridine ring of quinolines (3- and 4-aminoquinolines), the corresponding tetrahydrophenanthrolines were not obtain even in trifluoroethanol.

The formation of 6-aryltetrahydrophenanthrolines annulated with cyclopentene occurred with high diastereoselectivity. The ^1H NMR data (from the ratio of intensi-

ties of major and minor signals of vinyl protons H(8) or H(9) in the region δ 5.7–6.1) showed that the diastereomeric purity (*de*) of compounds **7**–**14** was no less than 90%. The spin-spin coupling constants for vicinal protons H(6) and H(6a) equal to 2.4 or 2.8 Hz, as well as that for protons H(6a) and H(9a) equal to 8.4 Hz (Tables 1 and 2) indicate a mutual *cis*-orientation of protons H(6), H(6a),

Table 1. ^1H and ^{13}C NMR spectra (δ , J/Hz) of compounds **7**–**10**

Group or atom	7		8		9		10	
	δ_{C}	δ_{H}	δ_{C}	δ_{H}	δ_{C}	δ_{H}	δ_{C}	δ_{H}
C(2)H	149.30	8.83 d, $J = 3.2$	149.36	8.89 d, $J = 3.2$	149.28	8.83 d, $J = 3.2$	149.32	8.84 d, $J = 3.2$
C(3)H	119.63	7.32 dd, $J = 8.0, 3.2$	119.72	7.21 dd, $J = 8.0, 3.2$	119.66	7.32 dd, $J = 8.0, 3.2$	119.77	7.35 dd, $J = 8.0, 3.2$
C(4)H	128.27	8.12 d, $J = 8.0$	128.26	8.07 d, $J = 8.0$	128.21	8.13 d, $J = 8.0$	128.28	8.16 d, $J = 8.0$
C(4a)	118.62	—	118.67	—	118.70	—	118.69	—
C(4b)	147.57	—	147.55	—	147.51	—	147.46	—
C(6)H	58.20	4.77 d, $J = 2.4$	57.71	4.70 d, $J = 2.4$	57.04	5.12 d, $J = 2.4$	57.91	4.84 d, $J = 2.4$
C(6a)H	46.07	3.27 td, $J = 8.4, 2.4$	45.83	3.08 td, $J = 8.4, 2.4$	43.46	3.27 td, $J = 8.4, 2.4$	45.79	3.14 td, $J = 8.4, 2.4$
C(7)H ₂	31.38	1.92 dd, $J = 15.6, 8.4$	31.27	1.89 dd, $J = 15.6, 8.4$	31.56	1.91 dd, $J = 15.6, 8.4$	31.23	1.88 dd, $J = 15.6, 8.4$
C(8)H	130.90	5.70 m (5.77 m)*	131.47	5.68 m (5.76 m)*	130.71	5.68 m (5.75 m)*	130.73	5.70 m (5.75 m)*
C(9)H	133.72	5.98 m (6.08 br.s)*	133.66	5.95 m (6.06 br.s)*	133.80	5.96 m (6.09 br.s)*	133.64	5.99 m (6.07 br.s)*
C(9a)H	46.82	4.29 d, $J = 8.4$	46.64	4.25 d, $J = 8.4$	46.53	4.30 d, $J = 8.4$	46.67	4.31 d, $J = 8.4$
C(9b)	120.81	—	120.76	—	120.99	—	120.85	—
C(10)H	131.13	7.47 d, $J = 8.8$	131.01	7.36 d, $J = 8.8$	131.11	7.45 d, $J = 8.8$	131.06	7.46 d, $J = 8.8$
C(11)H	119.96	7.58 d, $J = 8.8$	120.28	7.53 d, $J = 8.8$	120.21	7.58 d, $J = 8.8$	120.34	7.59 d, $J = 8.8$
C(11a)	139.89	—	139.41	—	139.72	—	139.31	—
C(1')	142.59	—	144.74	—	129.67 d, $^2J_{\text{CF}} = 12.0$	—	146.63	—
C(2')	—	—	—	—	160.17 d, $^1J_{\text{CF}} = 245.0$	—	—	—
C(2')H	128.72	7.56 d, $J = 4.8$	129.78	7.44 s	—	—	125.67	7.69 dd, $J = 8.8, 2.8$
C(3')	—	—	135.93	—	—	—	—	—
C(3')H	126.68	7.46 m	—	—	115.45 d, $^2J_{\text{CF}} = 21$	7.78 dd, $J_{\text{CF}} = 8.0,$ $J_{\text{H,H}} = 8.0$	127.01	7.69 dd, $J = 8.8, 2.8$
C(4')	—	—	—	—	—	—	122.79	—
C(4')H	127.59	7.38 m	127.71	7.30 m	127.34 d, $^3J_{\text{CF}} = 4$	7.12 dd, $J = 8.0$	—	—
C(5')H	126.68	7.46 m	124.87	7.30 m	124.38 d, $^4J_{\text{CF}} = 3$	7.26 m	127.01	7.69 dd, $J = 8.8, 2.8$
C(6')H	128.72	7.56 d, $J = 4.8$	126.73	7.30 m	129.42 d, $^3J_{\text{CF}} = 8$	7.36 m	125.64	7.69 dd, $J = 8.8, 2.8$
CF ₃	—	—	—	—	—	—	125.50 q, $^1J_{\text{CF}} = 270$	—
NH	—	4.49 br.s	—	4.45 br.s	—	4.35 br.s	—	4.49 br.s

* Chemical shifts δ_{H} C(8)H and C(9)H for minor 6*R*'-diastereomers are given in parentheses.

Table 2. ^1H and ^{13}C NMR spectra (δ , J/Hz) of compounds **11–14**

Group or atom	11		12		13		14	
	δ_{C}	δ_{H}	δ_{C}	δ_{H}	δ_{C}	δ_{H}	δ_{C}	δ_{H}
C(1)H	152.72	9.11 s	152.67	9.22 s	152.74	9.12 s	152.76	9.12 s
C(3)H	142.35	8.45 d, $J = 6.0$	142.39	8.42 d, $J = 6.0$	142.38	8.46 d, $J = 6.0$	142.51	8.47 d, $J = 6.0$
C(4)H	113.17	7.53 d, $J = 6.0$	113.24	7.54 d, $J = 6.0$	113.08	7.54 d, $J = 6.0$	113.05	7.55 d, $J = 6.0$
C(4a)	126.30	—	126.35	—	126.38	—	126.37	—
C(4b)	139.11	—	138.68	—	138.95	—	138.53	—
C(6)H	58.04	4.77 d, $J = 2.8$	57.51	4.50 s	50.91	5.11 d, $J = 2.8$	57.74	4.83 d, $J = 2.8$
C(6a)H	46.12	3.15, td, $J = 8.4, 2.8$	45.88	3.06 td, $J = 8.4, 2.8$	43.48	3.28 td, $J = 8.4, 2.8$	45.84	3.15 td, $J = 8.4, 2.8$
C(7)H ₂	31.39	1.92 dd, $J = 15.6, 8.4$ 2.73 m	31.29	1.86 dd, $J = 15.6, 8.4$ 2.63 m	31.57	1.91 td, $J = 15.6, 8.4$ 2.68 m	31.24	1.87 dd, $J = 15.6, 8.4$ 2.68 m
C(8)H	131.22	5.71 m (5.79 br.s)*	131.07	5.67 br.s (5.75 br.s)*	131.02	5.69 m (5.79 br.s)*	131.03	5.70 m (5.78 m)*
C(9)H	133.34	5.96 m (6.06 br.s)*	133.30	5.93 br.s (6.08 br.s)*	133.42	5.94 m (6.05 br.s)*	133.28	5.96 m (6.06 m)*
C(9a)H	47.09	4.30 d, $J = 8.4$	46.89	4.23 d, $J = 8.4$	46.81	4.30 d, $J = 8.4$	47.61	4.31 d, $J = 8.4$
C(9b)	124.36	—	124.29	—	124.50	—	124.37	—
C(10)H	128.74	7.46 d, $J = 8.0$	128.67	7.29 d, $J = 8.0$	128.77	7.39 d, $J = 8.0$	128.64	7.32 d, $J = 8.0$
C(11)H	117.83	7.43 d, $J = 8.0$	118.10	7.39 d, $J = 8.0$	118.11	7.41 d, $J = 8.0$	118.29	7.41 d, $J = 8.0$
C(11a)	127.72	—	127.63	—	128.04	—	127.69	—
C(1')	142.35	—	134.62	—	129.61	—	143.23	—
C(2')	—	—	—	—	160.15 q, $^1J_{\text{CF}} = 245.0$	—	—	—
C(2')H	126.65	7.42 m	130.01	7.35 m	—	—	127.00	7.70 dd, $J = 8.8, 2.8$
C(3')H	127.62	7.42 m	—	—	115.44 d, $^2J_{\text{CF}} = 21$	7.12 dd, $J_{\text{CF}} = 8.0,$ $J_{\text{H,H}} = 8.0$	125.69	7.70 dd, $J = 8.8, 2.8$
C(3')	—	—	144.64	—	—	—	—	—
C(4')H	128.74	7.42 m	126.75	7.35 m	127.33 d, $^3J_{\text{CF}} = 4.0$	7.28	—	—
C(4')	—	—	—	—	—	—	146.52	—
C(5')H	128.74	7.42 m	127.74	7.35 m	124.42 d, $^4J_{\text{CF}} = 3.0$	7.37	125.69	7.70 dd, $J = 8.8, 2.8$
C(6')H	126.65	7.42 m	124.84	7.35 m	128.98 d, $^3J_{\text{CF}} = 27.0$	7.79 t, $J = 8.0$	127.00	7.70 dd, $J = 8.8, 2.8$
CF ₃	—	—	—	—	—	—	125.50 q $^1J_{\text{CF}} = 270$	—
NH	—	4.51 br.s	—	4.66 br.s	—	4.37 br.s	—	4.50 br.s

* Chemical shifts δ_{H} C(8)H and C(9)H for minor 6*R**-diastereomers are given in parentheses.

and H(9a) and the *S**, *R**, and *S** relative configuration of asymmetric atoms C(6), C(6a), and C(9a), respectively. According to the data of the work,⁹ the minor diastereomers differ from the major ones in the configuration of carbon atom C(6) bearing the aryl substituent, *i.e.*, the minor diastereomers have the 6*R**, 6*aR**, and 9*aS** relative configuration of the chiral centers.

The signals in the ^1H and ^{13}C NMR spectra of synthesized compounds (see Tables 1 and 2) were assigned using 1D and 2D ^1H and ^{13}C NMR procedures (JMOD, HSQC, HMBC, COSY, NOESY). The mass spectra MALDI TOF of compounds **7–14** showed the presence of the corresponding molecular ions.

In conclusion, a three-component condensation in $\text{CF}_3\text{CH}_2\text{OH}$ of aminoquinolines, aromatic aldehydes, and cyclopentadiene in the presence of TFA as a catalyst gives rise to (6*S**, 6*aR**, 9*aS**)-6-aryl-6,6a,7,9a-tetrahydro-5*H*-cyclopenta[*c*]-1,7- and -1,8-phenanthrolines, which are structural analogues of alkaloids and diazasteroids.

Experimental

^1H and ^{13}C NMR spectra were recorded on a Bruker Avance-400 spectrometer (400.13 MHz (^1H) and 100.62 (^{13}C) MHz) in CDCl_3 , using SiMe_4 as an internal standard. Homo- and heteronuclear procedures COSY, HSQC, and HMBC were carried out

according to the Bruker standard procedures. Mass spectra were obtained on a Bruker-Autoflex III instrument in the MALDI TOF regime with registration of positive ions and using α -cyano-4-hydroxycinnamic acid as a matrix. Melting points were measured on a Boetius heating microstage. Elemental analysis was performed on a Carlo Erba EA-1108 CHNS-O-analyzer. Column chromatography was carried out on KSKG silica gel, 100/200. Silufol plates covered with SiO₂ was used for TLC monitoring, visualizing with a solution of vanillin in ethanol acidified with sulfuric acid.

The starting compounds **1–6** were purchased from Acros Organics. ¹H and ¹³C NMR spectra of compounds **7–10** and **11–14** are given in Tables 1 and 2, respectively.

Synthesis of 6-aryl-6,6a,7,9a-tetrahydro-5H-cyclopenta[*c*]-1,7- (7–10) and 6-aryl-6,6a,7,9a-tetrahydro-5H-cyclopenta[*c*]-1,8-phenanthrolines (11–14) (general procedure). The compound CF₃COOH (0.08 mL, 1 mmol), a freshly distilled cyclopentadiene (0.33 mL, 4 mmol), and the corresponding aldehyde **3–6** (1 mmol) were sequentially added to a solution of aminoquinoline **1** or **2** (144 mg, 1 mmol) in anhydrous CF₃CH₂OH (15 mL) (Ar, ~25 °C). The reaction mixture was stirred at room temperature until the amine disappeared (2–3 h, TLC monitoring, eluent ethyl acetate). The solvent was evaporated, a saturated solution of NaHSO₃–NaHCO₃ was added to the residue until neutrality (~5 mL), followed by extraction with ethyl acetate (3×10 mL). The organic layer was concentrated, the residue was subjected to chromatography (SiO₂, *n*-hexane/ethyl acetate, 4 : 1) to isolate the corresponding 1,7- (7–10) or 1,8-phenanthrolines (11–14).

(6S*,6aR*,9aS*)-6-Phenyl-6,6a,7,9a-tetrahydro-5H-cyclopenta[*c*][1,7]phenanthroline (7). The yield was 51%, *de* 92% (from the ratio of signal intensities at δ 5.98 and 6.08), *R*_f 0.49 (ethyl acetate), m.p. 102–104 °C (*n*-hexane). MS (MALDI TOF), *m/z*: 299 [M + H]⁺. Found (%): C, 84.60; H, 6.12; N, 9.28. C₂₁H₁₈N₂. Calculated (%): C, 84.56; H, 6.04; N, 9.40.

(6S*,6aR*,9aS*)-6-(*m*-Chlorophenyl)-6,6a,7,9a-tetrahydro-5H-cyclopenta[*c*][1,7]phenanthroline (8). The yield was 68%, *de* 90% (from the ratio of signal intensities at δ 5.95 and 6.06), *R*_f 0.40 (ethyl acetate), m.p. 97–99 °C (*n*-hexane). MS (MALDI TOF), *m/z*: 333 [M + H]⁺. Found (%): C, 75.93; H, 5.18; Cl, 10.61; N, 8.50. C₂₁H₁₇ClN₂. Calculated (%): C, 75.90; H, 5.12; Cl, 10.69; N, 8.43.

(6S*,6aR*,9aS*)-6-(*o*-Fluorophenyl)-6,6a,7,9a-tetrahydro-5H-cyclopenta[*c*][1,7]phenanthroline (9). The yield was 70%, *de* 94% (from the ratio of signal intensities at δ 5.96 and 6.09), *R*_f 0.43 (ethyl acetate), m.p. 90–92 °C (*n*-hexane). MS (MALDI TOF), *m/z*: 317 [M + H]⁺. Found (%): C, 79.64; H, 5.28; N, 8.69. C₂₁H₁₇FN₂. Calculated (%): C, 79.75; H, 5.40; N, 8.86.

(6S*,6aR*,9aS*)-6-[*p*-(Trifluoromethyl)phenyl]-6,6a,7,9a-tetrahydro-5H-cyclopenta[*c*][1,7]phenanthroline (10). The yield was 51%, *de* 97% (from the ratio of signal intensities at δ 5.99 and 6.07), *R*_f 0.48 (ethyl acetate), m.p. 120–122 °C (*n*-hexane). MS (MALDI TOF), *m/z*: 367 [M + H]⁺. Found (%): C, 72.01; H, 4.58; N, 7.51. C₂₂H₁₇F₃N₂. Calculated (%): C, 72.13; H, 4.64; N, 7.65.

(6S*,6aR*,9aS*)-6-Phenyl-6,6a,7,9a-tetrahydro-5H-cyclopenta[*c*][1,8]phenanthroline (11). The yield was 56%, *de* 90% (from the ratio of signal intensities at δ 5.96 and 6.06), *R*_f 0.47 (ethyl acetate), m.p. 60–62 °C (*n*-hexane). MS (MALDI TOF),

m/z: 299 [M + H]⁺. Found (%): C, 84.67; H, 6.15; N, 9.32. C₂₁H₁₈N₂. Calculated (%): C, 84.56; H, 6.04; N, 9.40.

(6S*,6aR*,9aS*)-6-(*m*-Chlorophenyl)-6,6a,7,9a-tetrahydro-5H-cyclopenta[*c*][1,8]phenanthroline (12). The yield was 70%, *de* 90% (from the ratio of signal intensities at δ 5.93 and 6.08), *R*_f 0.40 (ethyl acetate), m.p. 89–91 °C (*n*-hexane). MS (MALDI TOF), *m/z*: 333 [M + H]⁺. Found (%): C, 75.76; H, 5.23; Cl, 10.42; N, 8.29. C₂₁H₁₇ClN₂. Calculated (%): C, 75.90; H, 5.12; Cl, 10.69; N, 8.43.

(6S*,6aR*,9aS*)-6-(*o*-Fluorophenyl)-6,6a,7,9a-tetrahydro-5H-cyclopenta[*c*][1,8]phenanthroline (13). The yield was 70%, *de* 94% (from the ratio of signal intensities at δ 5.94 and 6.05), *R*_f 0.42 (ethyl acetate), m.p. 58–60 °C (*n*-hexane). MS (MALDI TOF), *m/z*: 317 [M + H]⁺. Found (%): C, 79.87; H, 5.64; N, 8.73. C₂₁H₁₇FN₂. Calculated (%): C, 79.75; H, 5.40; N, 8.86.

(6S*,6aR*,9aS*)-6-[*p*-(Trifluoromethyl)phenyl]-6,6a,7,9a-tetrahydro-5H-cyclopenta[*c*][1,8]phenanthroline (14). The yield was 62%, *de* 94% (from the ratio of signal intensities at δ 5.96 and 6.06), *R*_f 0.50 (ethyl acetate), m.p. 52–54 °C (*n*-hexane). MS (MALDI TOF), *m/z*: 367 [M + H]⁺. Found (%): C, 72.23; H, 4.60; N, 7.58. C₂₂H₁₇F₃N₂. Calculated (%): C, 72.13; H, 4.64; N, 7.65.

The authors are grateful to Prof. L. M. Khalilov for discussion of ¹H and ¹³C NMR spectra.

This work was financially supported by the Russian Foundation for Basic Research (Project No. 14-03-00286) and the Presidium of the Russian Academy of Sciences (Program "Fundamental Science to Medicine").

References

1. K. Saeki, T. Matsuda, T. Kato, S. Matsui, K. Fukuhara, N. Miyata, *Biolog. Pharm. Bull.*, 2003, **26**, 448.
2. M. Duszyk, L. Mac Vinish, A. W. Guthbert, *Brit. J. Pharm.*, 2001, **134**, 853.
3. N. G. Kozlov, A. B. Tereshko, *Russ. J. Org. Chem. (Engl. Transl.)*, 2010, **46**, 1223 [*Zh. Org. Khim.*, 2010, **46**, 1221].
4. P. J. Gregoire, J. M. Mellor, G. D. Merriman, *Tetrahedron Lett.*, 1991, **32**, 7099.
5. J. M. Mellor, G. D. Merriman, *Steroids*, 1995, **60**, 693.
6. A. G. Tolstikov, L. M. Khalilov, R. G. Savchenko, D. V. Nedopekin, V. A. Glushkov, G. F. Krainova, I. V. Glukhov, M. Yu. Antipin, V. N. Odinkov, *Russ. Chem. Bull. (Int. Ed.)*, 2009, **58**, 1991 [*Izv. Akad. Nauk, Ser. Khim.*, 2009, 1929].
7. A. G. Tolstikov, R. G. Savchenko, D. V. Nedopekin, S. R. Afon'kina, E. S. Lukina, V. N. Odinkov, *Russ. Chem. Bull. (Int. Ed.)*, 2011, **60**, 160 [*Izv. Akad. Nauk, Ser. Khim.*, 2011, 153].
8. A. G. Tolstikov, R. G. Savchenko, E. S. Lukina, D. V. Nedopekin, V. N. Odinkov, *Russ. Chem. Bull. (Int. Ed.)*, 2013, **62**, 203 [*Izv. Akad. Nauk, Ser. Khim.*, 2013, 203].
9. V. A. Glushkov, A. G. Tolstikov, *Russ. Chem. Rev. (Engl. Transl.)*, 2008, **77**, 137.

Received December 12, 2013;
in revised form March 25, 2014